Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
WEST LAFAYETTE, Ind., Feb. 24, 2016 -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, Mar. 2, at 4:30 p.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section of the Company’s website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
The webcast will be recorded and available on the Company’s website for one week following the call.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
